Bailard
REGN icon

Bailard’s Regeneron Pharmaceuticals REGN Stock Holding History

Bailard’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.56M Hold
3,376
– – 0.05% 225
2026
Q2 		$2.1M Sell
3,376
-2
-0.1% -$1.36K 0.04% 256
2026
Q1 		$2.61M Buy
3,378
+4
+0.1% +$3.06K 0.06% 208
2025
Q4 		$2.6M Sell
3,374
-105
-3% -$71.3K 0.06% 204
2025
Q3 		$1.96M Sell
3,479
-122
-3% -$69K 0.04% 242
2025
Q2 		$1.89M Sell
3,601
-433
-11% -$242K 0.04% 248
2025
Q1 		$2.56M Sell
4,034
-9,388
-70% -$6.46M 0.07% 206
2024
Q4 		$9.6M Buy
13,422
+1,236
+10% +$1.04M 0.24% 95
2024
Q3 		$12.8M Buy
12,186
+98
+0.8% +$109K 0.33% 72
2024
Q2 		$12.7M Sell
12,088
-56
-0.5% -$54.3K 0.35% 64
2024
Q1 		$11.7M Buy
12,144
+41
+0.3% +$39K 0.32% 75
2023
Q4 		$10.6M Sell
12,103
-31
-0.3% -$25.5K 0.31% 74
2023
Q3 		$10M Buy
12,134
+294
+2% +$231K 0.33% 65
2023
Q2 		$8.51M Buy
11,840
+2,486
+27% +$1.92M 0.3% 76
2023
Q1 		$7.69M Buy
9,354
+284
+3% +$214K 0.28% 84
2022
Q4 		$6.54M Buy
9,070
+207
+2% +$153K 0.25% 92
2022
Q3 		$6.1M Buy
8,863
+2,732
+45% +$1.72M 0.25% 91
2022
Q2 		$3.62M Buy
6,131
+5,831
+1,944% +$3.79M 0.14% 136
2022
Q1 		$210K Buy
+300
New +$190K 0.01% 662
2016
Q1 		– Sell
-1,000
Closed -$543K – 332
2015
Q4 		$543K Buy
+1,000
New +$542K 0.24% 134

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
Atwood & Palmer
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
PensionDanmark
PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

Bailard's REGN Position: Q3 2026 in Review

Bailard held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 3,376 shares worth $2.56M. The position accounts for 0.05% of the portfolio, ranked #225.

Bailard first reported a position in REGN in Q4 2015 and has held it in 20 quarters since. The position peaked at $12.8M in Q3 2024. 207 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Bailard held 3,376 shares of Regeneron Pharmaceuticals worth $2.56M as of Q3 2026.
  • Bailard left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.05% of Bailard's portfolio in Q3 2026, its #225 holding.
  • Bailard first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 20 quarters since.
  • Bailard's Regeneron Pharmaceuticals position peaked at $12.8M in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.